Impact of metabolic syndrome and C-reactive protein on outcome after coronary stenting

Journal of Endocrinological Investigation

Volumn 32, Issue 4, 2009, Pages 383-386

  Iturry Yamamoto, G R ^a   Zago, A C ^a   Moriguchi, E H ^a   Manfroi, W C ^a   Camargo, J L ^a   Gross, J L ^a   Zago, A J ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

C reactive protein; Clinical restenosis; Inflammation; Major adverse clinical events; Metabolic syndrome; Stent

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT; TICLOPIDINE; TRIACYLGLYCEROL;

ADULT; BODY MASS; CORONARY STENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NOTE; OBESITY; RESTENOSIS; REVASCULARIZATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; C-REACTIVE PROTEIN; CORONARY RESTENOSIS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; STENTS;

EID: 70349512013     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345730     Document Type: Note

References (27)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497
2. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112: 2735-2752
3. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112: 3066-3072 (Pubitemid 43113437)
4. Eberly LE, Prineas R, Cohen JD, et al; Multiple Risk Factor Intervention Trial Research Group. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006, 29: 123-130
5. Marroquin OC, Kip KE, Kelley DE, et al; Women's Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004, 109: 714-721
6. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109: 2818-2825
7. Rana JS, Monraats PS, Zwinderman AH, et al; GENDER study. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 2005, 28: 873-877
8. Hoffmann R, Stellbrink E, Schröder J, et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol 2007, 100: 1347-1352 (Pubitemid 47576009)
9. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 1999, 83: 1617-1622 (Pubitemid 29288003)
10. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997, 30: 1428-1436 (Pubitemid 27486458)
11. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002, 40: 2082-2089
12. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110: 1245-1250 (Pubitemid 39202340)
13. Girman CJ, Rhodes T, Mercuri M, et al; 4S Group and the AF-CAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93: 136-141 (Pubitemid 38058719)
14. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004, 109: 42-46 (Pubitemid 38056019)
15. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998, 32: 1866-1873 (Pubitemid 29010448)
16. Abizaid A, Komowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998, 32: 584-589 (Pubitemid 28435240)
17. Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005, 45: 198-203. (Pubitemid 40094725)
18. Chen LC, Chen YH, Lin SJ, et al. Clinical and angiographic determinants of adverse cardiac events in patients with stent restenosis. Catheter Cardiovasc Interv 2002, 55: 331-337
19. Lerakis S, El-Chami MF, Patel AD, et al. Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting. Am J Med Sci 2006, 331: 270-273 (Pubitemid 43804605)
20. Gurm HS, Whitlow PL, Kip KE; BARI Investigators. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 2002, 39: 834-840
21. Gurm HS, Brennen DM, Booth J, Tcheng JE, Lincoff AM, Topol EJ. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002, 90: 42-45 (Pubitemid 34671201)
22. Rana JS, Mittleman MA, Ho KK, Cutlip DE. Obesity and clinical restenosis after coronary stent placement. Am Heart J 2005, 150: 821-826 (Pubitemid 41396521)
23. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108: 414-419 (Pubitemid 36935533)
24. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107: 391-397
25. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 2001, 25: 1047-1056 (Pubitemid 32566061)
26. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005, 149: 54-60. (Pubitemid 40126490)
27. Win HK, Caldera AE, Maresh K, et al; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007, 297: 2001-2009